Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study

ConclusionEliapixant demonstrated efficacy and a favorable taste tolerability profile in RCC. However, a drug-induced liver injury contributed to intensified liver monitoring in clinical trials with eliapixant and discontinuation of the entire development program in all indications by Bayer AG.Trial RegistrationClinicalTrials.gov identifier NCT04562155; registered September 18, 2020.
Source: Lung - Category: Respiratory Medicine Source Type: research